Afatinib* (GIOTRIF®) is approved as a monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. In most countries it is restricted to EGFR tyrosine kinase inhibitor (TKI)-naïve patients.

Afatinib is also approved in some countries including the US and the EU for the treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing (on or) after platinum-based chemotherapy.1



Afatinib (GIOTRIF®) summary of product characteristics, May 2018 (Accessed: September 2020).

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information. 


© 2021 Boehringer Ingelheim International GmbH. All rights reserved.


Page last updated: January 2021